Repligen Target Price

Analysts' average 12-month price target for Repligen is $150.

Get informed when a big investor buys or sells

+ Follow

Share Price

$167.6

Average Target Price

$154.00

8.1% downside

3 analysts in the last 4 months

High: $160 | Low: $142

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-07-06	Evercore ISI	$160	4.5% downside
2026-05-14	RBC CapitalDan Leonard	$160	4.5% downside
2026-05-05	JefferiesMatthew Stanton	$142	15.3% downside
2026-04-20	Canaccord Genuity	$145	13.5% downside
2026-04-17	Redburn Partners	$160	4.5% downside
2026-04-14	BarclaysLuke Sergott	$145	13.5% downside
2026-01-16	UBSDan Leonard	$200	19.3% upside
2025-12-15	Wells Fargo	$190	13.4% upside
2025-12-15	Barclays	$200	19.3% upside
2025-10-29	Canaccord Genuity	$165	1.6% downside
2025-10-29	Barclays	$175	4.4% upside
2025-10-28	JefferiesMatthew Stanton	$160	4.5% downside
2025-10-02	BarclaysLuke Sergott	$160	4.5% downside
2025-10-01	HSBC	$150	10.5% downside
2025-09-02	RBC Capital	$205	22.3% upside
2024-11-12	KeyBancPaul Knight	$220	31.3% upside
2024-07-31	J.P. MorganRachel Vatnsdal	$200	19.3% upside
2024-07-31	UBSElizabeth Garcia	$185	10.4% upside
2024-06-26	Deutsche BankJustin Bowers	$155	7.5% downside
2024-06-21	Stifel NicolausDaniel Arias	$207	23.5% upside
2023-01-06	Leerink Partners	$200	19.3% upside
2022-12-14	Deutsche Bank	$180	7.4% upside
2022-12-07	RBC Capital	$190	13.4% upside
2022-04-28	Leerink Partners	$220	31.3% upside

Repligen (RGEN) FAQ

Repligen posts a target price of $150. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $150 for RGEN means covering analysts, on average, see the stock 8.1% downside of $167.6 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for RGEN's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Repligen's other metric pages and overview cover the third.

Judging Repligen against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $150 here, then scan peer and history charts to see if the gap is persistent.